Sciascia Thomas

Chief Scientific OfficerTrevi Therapeutics, Inc. (TRVI) · full profile →Form 4 · filed Aug 16, 2024
Net Selling
Open-Market Buys
$0
Open-Market Sells
$87K
Net Open-Market Flow
-$87K
Transactions
9
6 non-derivative · 3 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Aug 16, 2024Option exercise(M)19K$1.43$27K239K
Aug 16, 2024Sell(S)19K$2.76$52K220K
Aug 15, 2024Sell(S)13K$2.79$36K220K
Aug 15, 2024Option exercise(M)13K$1.43$18K233K
Aug 14, 2024Option exercise(M)100$1.43$143220K
Aug 14, 2024Sell(S)100$2.75$275220K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Aug 16, 2024Option exercise(M)19K$016K
Aug 15, 2024Option exercise(M)13K$035K
Aug 14, 2024Option exercise(M)100$048K

Transaction Codes

M
Option exercise / conversion
S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0000950170-24-098117) within minutes of acceptance. Every field above traces to the original document. Verify it directly: